|Basis of Allotment|
(This Is only an advertisement for Information purposes and not a Prospectus announcement.)
R J BIO-TECH LIMITED
Our Company was incorporated as "R J Bio-Tech Private Limited"under
the provisions of the Companies Act, 1956 vide
Registered Office: Siddharth Arcade, Opp.MTDC,
Railway Station Road, Aurangabad - 431005, Maharashtra, India.
PROMOTERS OF THE COMPANY: MR. RAGHAVENDRA JOSHI, MRS. MEENA JOSHI AND MR. SHASHIKANT SHASTRI
PUBLIC ISSUE OF 25,02,000 EQUITY SHARES OF RS. 10 EACH FOR CASH AT A PRICE OF RS. 20 PER EQUITY SHARE (THE "ISSUE PRICE") (INCLUDING A SHARE PREMIUM OF Rs. 10 PER EQUITY SHARE AGGREGATING Rs. 500.40 LAKHS (THE "ISSUE") BY OUR COMPANY, OF WHICH 1,26,000 EQUITY SHARES OF Rs. 10 EACH FULLY PAID WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 23,76,000 EQUITY SHARES OF Rs. 10 EACH FULLY PAID IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.43% AND 25.10%, RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF THE COMPANY.
This being a Fixed Price Issue and in terms of Prospectus dated 28th August, 2013 and as per Regulation 43 (4) of SEBI (ICDR) Regulations, 2009 wherein a minimum of 50.00% of the Net Offer to Public shall be initially made available to Retail Individual Investors. The balance net offer of shares to the public shall be made available for allotment to a) individual applicants other than retail investors and b) other investors including corporate bodies / institutions irrespective of no. of shares applied for. The unsubscribed portion of the net offer to any one of the categories specified in (a) or (b) shall/may be made available for allocation in any other category, if so required. Explanation: for the purpose of Regulation 43 (4) of SEBI (ICDR) Regulations, 2009, if the retail individual investor is entitled to more than fifty percent, on proportionate basis, the retail individual investors shall be allocated that higher percentage.
THE FACE VALUE OF EQUITY SHARES IS RS. 10 EACH. THE ISSUE PRICE
IS RS. 20/-.
The Equity Shares offered through the Prospectus are proposed to be listed on the SME platform of BSE Limited ("BSE") in terms of the chapter XB of the SEBI (ICDR) Regulations, 2009 as amended from time to time, Company is not required to obtain an in-principle approval for the shares being offered in this Issue. However Company has received an approval letter dated 13th March, 2013 from BSE for using its name in the offer document for listing of our Shares on the SME platform of BSE. The designated stock exchange is BSE Limited.
All Applicants were allowed to participate in the Issue through APPLICATION SUPPORTED BY BLOCKED AMOUNT ("ASBA") process by providing the details of the respective bank accounts in which the corresponding application amounts were blocked by Self Certified Syndicate Banks (the "SCSBs").
The Issue has received 150 applications for 28,98,000 Equity Shares (Including Market Maker Application of 1,26,000 Equity Shares) resulting 1.16 times subscription. After considering, technical rejections cases of 7 application for 1,92,000 Equity Shares, the Issue was subscribed 1.08 times. The details of the applications received in the Issue (before technical rejections) are as follows:
Detail of the Applications Received (Before Technical Rejection & withdrawal of application):
The details of applications rejected by the Registrar on technical grounds (including withdrawals) are detailed below:
Detail of the Applications Received (After Technical Rejection & withdrawal):
ALLOCATION: The Basis of Allotment was finalized in consultation with the Designated Stock Exchange - BSE Limited on 19th September, 2013.
A. Allocation to Market Maker (After Technical Rejections & Withdrawal): The Basis of Allotment to the Market Maker, at the issue price of Rs. 20/- per Equity Share, was finalised in consultation with BSE. The category was subscribed by 1.00 times. The total number of shares allotted in this category is 1,26,000 Equity shares in full out of reserved portion of 1,26,000 Equity Shares.
B. Allocation to Retail Individual Investors (After Technical Rejections & Withdrawal): The Basis of Allotment to the Retail Individual Investors, at the issue price of Rs. 20/- per Equity Share, was finalized in consultation with BSE. The category was subscribed by 0.22 times. Total number of shares allotted in this category is 2,64,000 Equity Shares. The category wise basis of allotment is as under:
C. Allocation to Non Retail Investors (After Technical Rejections & Withdrawal): The Basis of Allotment to the Non Retail Investors, at the issue price of Rs. 20/- per Equity Share, was finalized in consultation with BSE. The category was subscribed by 1.95 times. Total number of shares allotted in this category is 21,12,000 Equity Shares including spill over of 9,24,000 Equity Shares from retail category. The category wise basis of allotment is as under:
The Board of Directors of the Company at its meeting held on 20th September, 2013 has taken on record the Basis of Allocation of Equity Shares approved by the Designated Stock Exchange viz. BSE Ltd and has authorized the corporate action for the transfer of the Equity Shares / dispatch of share certificates to various successful applicants. The CAN-cum-Refund Orders and allotment advice and/or notices are being dispatched to the address of the Applicants as registered with the depositories / as filled in the application form on or before 21st September, 2013. Further, the instructions to Self Certified Syndicate Banks being processed on or prior to 20th September, 2013. In case the same is not received within 10 days, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for trading on the SME Platform of BSE Limited within Twelve working days from the date of the closure of the Issue. The trading is proposed to be commenced on or before September 25,2013 subject to receipt of listing and trading approvals from BSE Limited.
INVESTORS PLEASE NOTE
The details of the allotment made would also be hosted on the website of the Registrar to the Issue, Bigshare Services Private Limited at www.bigshareonline.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:
THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF R.J. BIO-TECH LIMITED.
Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus
R.J. BIO-TECH LIMITED is proposing, subject to market conditions and other considerations, a public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies Mumbai, Maharashtra. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, the Website of the Issuer Company at www. rjbiotech.com, the website of the Lead Manager at www.sarthi.in and the website of the BSE at www.bseindia.com. Investor should note that investment in equity shares involves a high degree of risk. For details, investors should refer to and rely on the Prospectus, including the section titled "Risk Factors" of the Prospectus, which has been filed with ROC. The Equity Shares have not been and will not be registered under the US Securities Act ("the Securities Act") or any state securities laws in United States and may not be issued or sold within the United States or to, or for the account or benefit of, 'US, persons" (as defined in Regulations under the securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933.